File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Rosiglitazone induces cardiac protein kinase C beta2 over-expression and increases ventricular mass in type 2 diabetic db/db mice

TitleRosiglitazone induces cardiac protein kinase C beta2 over-expression and increases ventricular mass in type 2 diabetic db/db mice
Authors
KeywordsBiology
Issue Date2009
PublisherFederation of American Societies for Experimental Biology. The Journal's web site is located at http://www.fasebj.org/
Citation
The 2009 Experimental Biology Meeting, New Orleans, LA., 18-22 April 2009. In The FASEB Journal, 2009, v. 23 meeting abstract suppl., abstract no. LB378 How to Cite?
AbstractRosiglitazone (RSG) treatment in type 2 diabetes has been associated with increased incidence and worsening of heart failure, but the mechanism is unknown. It has been shown that protein kinase C (PKC) β2 is over-expressed in failing human hearts (Circulation 1999;99:384-91) and that RSG-induced weight gain is attributable to increased activation of PKCβ in adipose tissue (FASEB J 2006;20:1203-5). Further, left ventricular mass is reported to be a predictor of heart failure (Eur Heart J 2008;29:741-747). We, therefore, hypothesized that RSG may induce PKCβ2 over-expression and increase ventricular mass of the hearts from db/db (D) mice, a mongenic model of obesity and features of type 2 diabetes. Diabetic mice were either untreated (D), treated with RSG (D+RSG) at 26 mg/kg/day or with RSG plus N-acetylcysteine (NAC, 1.4 g/kg/day) (D+RN), for 3 weeks; NAC can inhibit PKCβ via mechanisms independent of its antioxidant property. Both RSG or RSG+NAC reduced body weight (BW) relative to D group. However, RSG increased ventricular mass and heart weight/BW ratio, accompanied by 1.5-fold increase of myocardial PKCβ2 protein expression and activation as well as increased protein kinase B/AKT phosphorylation at serine-473 relative to D (all P<0.05). NAC prevented all these changes. RGS may have increased ventricular mass by inducing PKCβ2 over-expression.
Persistent Identifierhttp://hdl.handle.net/10722/63425
ISSN
2015 Impact Factor: 5.299
2015 SCImago Journal Rankings: 2.775

 

DC FieldValueLanguage
dc.contributor.authorXia, Zen_HK
dc.contributor.authorCarroll, Ren_HK
dc.contributor.authorWang, Fen_HK
dc.contributor.authorSeverson, DLen_HK
dc.date.accessioned2010-07-13T04:23:21Z-
dc.date.available2010-07-13T04:23:21Z-
dc.date.issued2009en_HK
dc.identifier.citationThe 2009 Experimental Biology Meeting, New Orleans, LA., 18-22 April 2009. In The FASEB Journal, 2009, v. 23 meeting abstract suppl., abstract no. LB378en_HK
dc.identifier.issn0892-6638en_HK
dc.identifier.urihttp://hdl.handle.net/10722/63425-
dc.description.abstractRosiglitazone (RSG) treatment in type 2 diabetes has been associated with increased incidence and worsening of heart failure, but the mechanism is unknown. It has been shown that protein kinase C (PKC) β2 is over-expressed in failing human hearts (Circulation 1999;99:384-91) and that RSG-induced weight gain is attributable to increased activation of PKCβ in adipose tissue (FASEB J 2006;20:1203-5). Further, left ventricular mass is reported to be a predictor of heart failure (Eur Heart J 2008;29:741-747). We, therefore, hypothesized that RSG may induce PKCβ2 over-expression and increase ventricular mass of the hearts from db/db (D) mice, a mongenic model of obesity and features of type 2 diabetes. Diabetic mice were either untreated (D), treated with RSG (D+RSG) at 26 mg/kg/day or with RSG plus N-acetylcysteine (NAC, 1.4 g/kg/day) (D+RN), for 3 weeks; NAC can inhibit PKCβ via mechanisms independent of its antioxidant property. Both RSG or RSG+NAC reduced body weight (BW) relative to D group. However, RSG increased ventricular mass and heart weight/BW ratio, accompanied by 1.5-fold increase of myocardial PKCβ2 protein expression and activation as well as increased protein kinase B/AKT phosphorylation at serine-473 relative to D (all P<0.05). NAC prevented all these changes. RGS may have increased ventricular mass by inducing PKCβ2 over-expression.-
dc.languageengen_HK
dc.publisherFederation of American Societies for Experimental Biology. The Journal's web site is located at http://www.fasebj.org/en_HK
dc.relation.ispartofThe FASEB Journal-
dc.subjectBiology-
dc.titleRosiglitazone induces cardiac protein kinase C beta2 over-expression and increases ventricular mass in type 2 diabetic db/db miceen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0892-6638&volume=23, Meeting abstract suppl., abstract no. LB378&spage=&epage=&date=2009&atitle=Rosiglitazone+induces+cardiac+protein+kinase+C+beta2+over-expression+and+increases+ventricular+mass+in+type+2+diabetic+db/db+miceen_HK
dc.identifier.emailXia, Z: zhengyuan_xia@yahoo.comen_HK
dc.identifier.hkuros162388en_HK
dc.identifier.volume23-
dc.identifier.issuemeeting abstract suppl.-
dc.description.otherThe Experimental Biology 2009, New Orleans, LA., 18-22 April 2009. In The FASEB Journal, 2009, v. 23 Meeting abstract suppl., abstract no. LB378-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats